This activity is supported by unrestricted educational grant from Oyster Point Pharma.
Upon completion of this activity, the participant should be able to:
Sponsored by:
Evolve is an approved COPE administrator.
This activity, COPE Activity Number 122011, is accredited by COPE for continuing education for optometrists.
This course is approved for 1.0 hours CE.
COPE Course ID: 73155-AS
COPE Activity ID: 122011
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Damon Dierker, OD (Moderator)
Director of Optometric Services
Eye Surgeons of Indiana
Indianapolis, IN
Kelly K. Nichols, OD, MPH, PhD, FAAO
Dean of the School of Optometry
University of Alabama at Birmingham
Birmingham, AL
Walt Whitley, OD, MBA, FAAO
Director of Referral Services
Residency Program Supervisor
Virginia Eye Consultants
Norfolk, VA
Patrick Vollmer, OD, FAAO
Vita Eye Clinic/Core Inc.
Shelby, NC
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Damon Dierker, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, Bio-Tissue, Carl Zeiss Meditec, Eyevance, Glaukos, Johnson & Johnson Vision, Kala, Lumenis, MacuLogix, Notal Vision, Novartis, Osmotica, Scope, Sight Sciences, and Sun Pharmaceutical Industries. Grant/Research Support: Allergan, Ocular Therapeutix, and Tarsus. Speaker’s Bureau: Alcon Vision, Allergan, Bio-Tissue, Eyevance, Glaukos, Kala Pharmaceuticals, Lumenis, MacuLogix, MacuHealth, Notal Vision, Novartis, Sun Pharmaceutical Industries, and TearLab.
Kelly K. Nichols, OD, MPH, PhD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Bruder, Dompé, HanAll Bio, Kala Pharmaceuticals, Novartis, Osmotica, Oyster Point Pharma, Sight Sciences, Thea, Tarsis, and Topivent. Grant/Research Support: Allergan, Kala Pharmaceuticals, NIH, and Tear Science. Stock/Shareholder: Alcon Vision, Acquiom, LacriScience, and Tear Film Innovations.
Walt Whitley, OD, MBA, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon Vision, Allergan, Bausch + Lomb, Bio-Tissue, Bruder Healthcare, Eyevance, Glaukos, Horizon Therapeutics, Johnson & Johnson Vision, Kala Pharmaceuticals, Notal Vision, Novartis, Ocular Therapeutix, Ocusoft, Oyster Point Pharma, Quidel, Regener-Eyes, RVL Pharmaceuticals, ScienceBased Health, Sun Pharmaceutical Industries, Tarsus Pharmaceuticals, TearLab, and Thea Pharmaceuticals. Speaker’s Bureau: Aerie Pharmaceuticals, Alcon Vision, Bausch + Lomb, Bio-Tissue, Eyevance, Novartis, ScienceBased Health, and Sun Pharmaceutical Industries. Share/Stockholder: Leo Lens Technology.
Patrick Vollmer, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board: Bausch Health, Mediprint Lens, and Oyster Point Pharma. Consultant: Novartis, Ora, and RVL Pharmaceuticals. Grant/Research Support: Aerie Pharmaceuticals, Aldeyra Therapeutics, Allergan, Allergan Aesthetics, Alcon Vision, Andover Eye, Bausch Health, Hanall Biopharma, Mallinckrodt Pharmaceuticals, Mediprint Lens, Mimetogen Pharmaceuticals, Mitotech, Novaliq, Nicox, Ora, Oyster Point Pharma, Palatin Technologies, ReGenTree, Sight Sciences, Tarsus Pharmaceuticals, and Visibly. Speaker’s Bureau: Bausch Health. Stock/Shareholder: Mediprint Lens.
The Evolve staff and planners have no financial relationships with commercial interests.
Michelle Dalton, writer, has no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Modern Optometry, or Oyster Point Pharma.
